Syndax Pharmaceuticals (SNDX) Reports First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Syndax Pharmaceuticals (SNDX) Reports First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals (SNDX) Tops Q3 EPS by 6c

November 7, 2019 5:46 PM EST

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47).

"We are pleased to have passed the final interim futility analysis of overall survival for E2112, our Phase 3 registration trial of entinostat plus exemestane in HR+, HER2- breast cancer, and anticipate the final overall survival readout in the... More